Skip to main content
. 2023 Feb 6;183(3):242–254. doi: 10.1001/jamainternmed.2022.6664

Figure 1. Study Flowchart.

Figure 1.

Eligible population included in the study cohort initiating SGLT2 or DPP-4 inhibitors between April 2013 and June 2021 before and after matching, overall and stratified by HbA1c baseline level. DPP-4 indicates dipeptidyl peptidase-4; HbA1c, hemoglobin A1c; PS, propensity score; SGLT2, sodium-glucose cotransporter 2.